Inhibitors of beta-hydroxylase for treatment of cancer
US9771356B2 · kind B2 · utility
2Cited by
4References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 20, 2013 |
| Grant date | Sep 26, 2017 |
| Priority date | — |
| Expiry date | Sep 20, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q1/26
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydroxylase (e.g., Asparatyl (asparaginyl) β-hydroxylase (ASPH)), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.